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Abstract  22 
Antimicrobial resistance is a growing global concern in human and veterinary medicine, 23 
with an ever-increasing void in the arsenal of clinicians. Novel classes of compounds 24 
including carbon monoxoide-releasing molecules (CORMs), for example the light-25 
activated metal complex [Mn(CO)3(tpa-3N)]Br, could be used as alternatives/to 26 
supplement traditional antibacterials. Avian pathogenic Escherichia coli (APEC) represent 27 
a large reservoir of antibiotic resistance and can cause serious clinical disease in poultry, 28 
with potential as zoonotic pathogens, due to shared serotypes and virulence factors with 29 
human pathogenic E. coli. The in vitro activity of [Mn(CO)3(tpa-3N)]Br against multidrug-30 
resistant APECs was assessed via broth microtitre dilution assays and synergy testing 31 
with colistin performed using checkerboard and time-kill assays. In vivo antibacterial 32 
activity of [Mn(CO)3(tpa-3N)]Br alone and in combination with colistin was determined 33 
using the Galleria mellonella wax moth larvae model. Animals were monitored for 34 
life/death, melanisation and bacterial numbers enumerated from larval haemolymph. In 35 
vitro testing produced relatively high [Mn(CO)3(tpa-3N)]Br minimum inhibitory 36 
concentrations (MICs) of 1024 mg/L. However, its activity was significantly increased with 37 
the addition of colistin, bringing MICs down to ≤32 mg/L. This synergy was confirmed in 38 
time-kill assays. In vivo assays showed that the combination of [Mn(CO)3(tpa-3N)]Br with 39 
colistin produced superior bacterial killing and significantly increased larval survival. In 40 
both in vitro and in vivo assays light activation was not required for antibacterial activity. 41 
This data supports further evaluation of [Mn(CO)3(tpa-3N)]Br  as a potential agent for 42 
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treatment of systemic infections in humans and animals, when used with permeabilising 43 
agents such as colistin. 44 
 45 
Keywords: Multidrug-resistant; avian pathogenic Escherichia coli; Synergy; in vivo; 46 
manganese complex.  47 
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Introduction 48 
Antimicrobial resistance is a growing global concern, with clinicians in human and 49 
veterinary medicine faced with reduced therapeutic options to treat patients with 50 
infections caused by multidrug-resistant bacteria [1]. Gram-negative bacteria such as 51 
Escherichia coli have in recent years been highlighted as potential super bugs, due to 52 
increasing antibiotic resistance to many classes of antibiotic. This issue, added to the lack 53 
of antibacterials in the pipeline that specifically target Gram-negative bacteria, has left an 54 
ever-increasing void in the arsenal of clinicians, as the number of effective antibiotics 55 
declines [2]. Antibacterials of last resort such as carbapenems and polymyxins are 56 
increasingly used as front line drugs. However, resistance to carbapenems via the 57 
production of carbapenemases, efflux or reduced permeability has been widely reported 58 
[3]. This has led to the revival of previously abandoned antibiotics including colistin 59 
(polymyxin E), fosfomycin and chloramphenicol. With the increased use of these 60 
antibiotics, a significant rise in resistance has followed, recently noted with the discovery 61 
of MCR-1, the plasmidic colistin-resistance gene, in China [4-5] and in other countries in 62 
both humans and animals.  63 
One potentially problematic group of pathogens are avian pathogenic E. coli 64 
(APEC). APECs make up part of the normal avian intestinal flora, but can cause serious 65 
clinical disease in poultry. Avian colibacillosis caused by APEC is an economically 66 
important infectious disease of domestic poultry. The aetiological agent responsible for 67 
colibacillosis is Escherichia coli, with the most commonly implicated serotypes being 68 
O1:K1, O2:K1 and O78:K80. Avian colibacillosis is a respiratory and systemic disease 69 
that exerts substantial welfare and economic costs on the poultry industry worldwide [6- 70 
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7]. Losses are incurred through mortality, condemnation of carcasses at slaughter, 71 
reduced productivity and costs associated with antibiotic treatment. Recent 72 
epidemiological evidence suggests that approximately 40% of mortalities from broiler 73 
flocks are associated with colibacillosis [8].  Avian colibacillosis is also responsible for up 74 
to 70% of mortality seen in broiler chicks 2-3 days after placement. Avian colibacillosis is 75 
a multifactorial disease and a number of risk factors are known, including prior or 76 
concurrent infection with respiratory viruses or Mycoplasma, stress and injury associated 77 
with formation of a social hierarchy, onset of sexual maturity and intense laying, as well 78 
as poor biosecurity, hygiene and ventilation [9]. Vaccination has proved successful for 79 
some APEC pathotypes, but the poultry industry is still reliant on antibiotics to treat APEC.  80 
There are several reports suggesting that APECs harbour an array of resistance 81 
genes such as blaCTX-M-1, blaCMY-2 and blaTEM [10]. As APECs share identical 82 
serotypes and many virulence factors with human pathogenic E. coli, their potential as 83 
zoonotic pathogens should also not be underestimated [11, 12].  84 
Alternatives to traditional antibacterials are investigated to supplement the growing 85 
need for antimicrobials. One group of potential drug candidates are carbon monoxide-86 
releasing molecules (CORMs) such as CORM-3, which have received attention due to 87 
their effectiveness as antibacterial agents [13]. Several novel CORMs, including those 88 
activated by light at a specific wavelength such as [Mn(CO)3(tpa-3N)]Br have potential 89 
for therapeutic use against Gram-negative bacteria including E. coli [14]. Although the 90 
mechanisms of this compound are not entirely understood, the proposed mechanisms 91 
include membrane disruption due to hydroxyradical production, interference of metal ion 92 
uptake and inhibition of respiration, due to CO binding to respiratory cytochromes. 93 
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Recent work has also demonstrated the antibacterial action of a novel tryptophan 94 
manganese(I) carbonyl complex (Trypto-CORM) against Neisseria gonorrohoeae, which 95 
in recent years has also shown increasing antibiotic resistance [15]. Previous data 96 
suggests that the manganese-coligand core of the title compound does not reach the 97 
intracellular environment of bacteria [14]. However, using a polymyxin such as colistin, to 98 
permeabilise the outer membrane, could facilitate entry of the metal complex and increase 99 
the compound's antibacterial activity. The aim of the studies described here was to 100 
evaluate the in vitro and in vivo activity of the manganese complex [Mn(CO)3(tpa-3N)]Br 101 
alone and in combination with colistin against multidrug-resistance strains of avian 102 
pathogenic E. coli. 103 
 104 
Materials and methods 105 
Bacterial isolates, antibiotics and media 106 
Avian pathogenic E. coli strains (n = 124) isolated from poultry farms across the UK were 107 
provided by Ridgeway Biologicals (Compton, UK). All strains were cultured on 108 
MacConkey agar for 16 h at 37 °C, aerobically and characterised by biochemical and 109 
molecular profiles. Stock cultures were stored in glycerol at -80°C. [Mn(CO)3(tpa-3N)]Br 110 
(USC-CN028) was synthesised at the University of Würzburg, in the laboratories of Prof 111 
Ulrich Schatzschneider according to a published procedure [16]. Colistin sulfate powder 112 
was purchased from Cambridge Biosciences (Cambridge, UK). Mueller Hinton 2 agar and 113 
Mueller Hinton 2 cation adjusted broth was purchased from SigmaAldrich (Dorset, UK). 114 
 115 
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Antibacterial assays 116 
Antibiotic susceptibility testing  117 
Antibiotic susceptibility testing of 24 commonly used antibiotics (ampicillin, ampicillin-118 
sulbactam, azithromycin, aztreonam, cefepime, cefotaxime, cefoxitin, cephalexin, 119 
chloramphenicol, ciprofloxacin, clavulanic acid-amoxicillin, colistin, doxycycline, 120 
ertapenem, fosfomycin, gentamicin, imipenem, meropenem, nalidixic acid, 121 
nitrofurantonin, pipacillin-tazobactam, tetracycline, trimethoprim-sulfamethoxazole and 122 
tigecycline) was performed using the disc diffusion assay on Mueller Hinton 2 agar, 123 
against all 124 APEC strains, using standard methods previously described [17]. Plates 124 
were incubated at 37 °C for 16 h, aerobically, after which zones of inhibition were 125 
recorded. Susceptibility/resistance was checked using breakpoints from the European 126 
Committee on Antimicrobial Susceptibility Testing [18]. A panel of strains resistant to ≥ 5 127 
antibiotic classes were selected for further study in order to determine the minimum 128 
inhibitory concentrations (MICs) of [Mn(CO)3(tpa-3N)]Br and colistin. 129 
 130 
Bacterial growth curves  131 
Prior to MIC testing, growth curves were performed on the test bacterial strains with and 132 
without exposure to UV light (365 nm) for 2.5 min, equivalent to that required for activation 133 
of the Mn complex. This was to undertaken to confirm that any antimicrobial activity could 134 
be attributed to the Mn complex and not exposure to the UV light. To perform the growth 135 
curves, a 1/1000 dilution of a 16 h broth culture, equating to approximately 106 CFU/mL 136 
was used for the starting inoculum. At set time intervals of 0, 2, 4, 6 and 24 h post 137 
inoculation, 100 μL samples were sampled, serially diluted and plated onto Mueller Hinton 138 
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2 agar. Colonies from the dilutions were enumerated after incubation at 37 °C for 16 h, 139 
aerobically. Growth curves were plotted used GraphPad Prism 6.0 to check for 140 
differences in growth kinetics +/- UV exposure. 141 
 142 
Minimum inhibitory concentrations 143 
Minimum inhibitory concentrations of [Mn(CO)3(tpa-3N)]Br and colistin were determined 144 
alone and in combination against seven multidrug-resistant isolates and performed in 96-145 
well microtitre plates using Mueller Hinton 2 broth. Assays were set up in checkerboard 146 
style with 2-fold decreasing concentrations of the Mn complex (512-0 mg/L) and colistin 147 
(8-0 mg/L) with a bacterial inoculum of 105 colony forming units (CFU) per mL. Plates 148 
were incubated at 37 °C, aerobically and checked for turbidity after 24 h. Where the MIC 149 
was not achieved, the dilution above the maximum dose was used for calculating the 150 
fractional inhibitory concentration indexes (FICIs). Fractional inhibitory concentration 151 
indexes were calculated using the following equation as previously described [19]. FICI = 152 
FIC of A (MIC of antibiotic A in combination with antibiotic B/MIC of antibiotic A alone) + 153 
FIC of B (MIC of antibiotic B in combination with antibiotic A/MIC of antibiotic B alone). 154 
FICI values of ≤ 0.5 suggest a synergistic interaction, > 0.5−1.0 as an additive effect, > 155 
1.0 to < 4 as indifference and a value of ≥ 4.0 was classed as an antagonistic effect [20]. 156 
All experiments were performed in triplicate (biological repeats), and results are 157 
presented as mean values. 158 
 159 
 160 
 161 
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Kill-kinetic assays  162 
Kill-kinetic assays were performed using strain 236/12. In brief, a 1/1000 dilution of a 16 163 
h, aerobic culture, equating to approximately 106 CFU/mL was used as the starting 164 
inoculum for each strain. To individual cultures, antimicrobials were added at final 165 
concentrations, which were as follows: [Mn(CO)3(tpa-3N)]Br (x 1 MIC), colistin (x 0.5/x 1 166 
MIC) and the Mn complex-colistin combination (x 1 MIC – x 0.5 MIC). Cultures were 167 
incubated at 37 °C under continuous agitation (225 rpm) for 24 h. At set time intervals of 168 
0, 2, 4, 6 and 24 h post inoculation, 100 μL samples were collected, serially diluted and 169 
plated onto Mueller Hinton 2 agar. Colonies from the dilutions were counted after 170 
incubation, aerobically at 37 °C for 20 h. Time−kill curves (CFU/mL vs time) were plotted 171 
using GraphPad Prism 6.0 software. Synergy was defined as bactericidal activity (≥2 log10 172 
difference in CFU/mL) of the combination compared to the single agent after 24 h 173 
incubation. Unpaired student t-tests were performed to check for significant variance. 174 
 175 
In vivo toxicity in Galleria mellonella 176 
In vivo testing was conducted using the standardised Galleria mellonella invertebrate 177 
model (TruLarvTM, Biosystems Technology, Exeter). In brief, ten larvae were injected via 178 
the left proleg with 40, 200, 400, 600 mg/kg of Mn complex freshly prepared in sterile 179 
phosphate buffered saline (PBS) or a PBS control. Immediately after administration of the 180 
Mn complex, all larvae were placed in a sterile petri dish, illuminated with UV light (365 181 
nm) (Uvitec LF206LS, Dutscher Scientific, Essex) for 2.5 min (Distance ~ 3 cm). The 182 
larvae then were incubated at 37 °C for 48 h, with survival recorded (live/dead via a lack 183 
of response to touch) at 0, 24 and 48 h post treatment. The experiment was repeated with 184 
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no exposure to UV light. All in vivo experiments were carried out in triplicate on 3 separate 185 
occasions. 186 
 187 
Inoculum testing  188 
To determine the optimum inoculum for larval killing (approx. 50 % mortality of larvae at 189 
24 h post infection), an inoculum test was performed. In brief, a 16 h culture of APEC 190 
strain 236/12 in Luria base broth was washed in PBS before being serially diluted in PBS. 191 
Colony forming units were determined by plating the dilutions on nutrient agar and 192 
incubating at 37 °C for 24 h. Ten G. mellonella larvae were infected with the 16 h culture 193 
dilutions, equating to 103, 104, 105 and 106 CFU/larvae, via a 10 µL injection into the left 194 
proleg. Larvae were incubated at 37 °C and scored for survival (live/dead) at 0, 24, 48, 195 
72 and 96 h.  196 
 197 
G. mellonella treatment assays 198 
Sixteen larvae were infected with 105 CFU/larvae of APEC strain 236/12 via a 10 µL 199 
injection in a left proleg. Within 30 min after infection, a second injection into a right proleg 200 
was administered of the Mn complex (20 mg/kg in PBS), colistin (0.625 mg/kg), a 201 
combination of Mn complex and colistin (20 + 0.625 mg/kg) or PBS +/- UV exposure for 202 
2.5 min at 365 nm post injection. Larvae were incubated at 37 °C and scored for survival 203 
(live/dead) at 0, 24, 48, 72 and 96 h.   204 
Melanisation scores for larvae were recorded over 72 h as an indicator of morbidity, 205 
based on a reversed scoring method previously published [21], whereby a score of 4 206 
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indicated total melanisation of the larvae, 2 equalled melanin spots over the larvae, 1 207 
equalled discolouration of the tail and a score of 0 equalled no melanisation.  208 
Bacterial enumeration from infected and treated larvae was performed over 24 h, 209 
by plating out larval haemolymph collected from larvae post-mortem. Larvae were 210 
injected with isolate 236/12 as described in the treatment assay and at 0, 2, 4, 6, 12 and 211 
24 h, haemolymph from 3 larvae was collected. In brief, larvae were placed in cold storage 212 
(-20 °C for 10 min) before being wiped with 70 % ethanol. A sterile scalpel was used to 213 
remove the tip of the tail and haemolymph collected into an Eppendorf tube on ice. 214 
Haemolymph (100 µL) was serially diluted in sterile PBS and dilutions were plated out on 215 
MacConkey 3 agar (Oxoid, Basingstoke, UK). Plates were incubated for 18 h at 37 °C, 216 
before bacterial enumeration was performed.  217 
All assays were performed in triplicate and mean values presented. Survival 218 
curves, melanisation scores and bacterial counts were plotted using GraphPad Prism 6.0 219 
software (San Diego, CA, USA). Analysis of survival curves was performed using the log 220 
rank test, with a p value of ≤ 0.05 indicating statistical significance [22]. Unpaired student 221 
t-tests were performed to check for significant variance in bacterial counts at 24 h. 222 
 223 
Results and discussion 224 
Results from the antibiotic susceptibility testing indicated that 45 out of 124 APEC 225 
strains tested were multidrug-resistant (Table 1, S1 Table), with resistance observed 226 
against > 2 antibiotic classes in relation to breakpoints set by the European committee on 227 
antimicrobial susceptibility testing [18]. Of these strains 7 were resistant to > 5 antibiotic 228 
classes. No strains exhibited resistance to carbapenems or polymyxins.  229 
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Growth kinetics analysis from cultures with and out exposure to UV light (365 nm, 230 
2.5 min) showed no significant difference (P >0.5) in growth rates or growth numbers at 231 
24 h (Fig. 1, S2 Table). This supported previous studies and confirmed that any 232 
antimicrobial activity would be due to the manganese carbonyl complex and not the UV 233 
light exposure [14].  234 
 235 
Table 1. Phenotypic resistance of 124 avian pathogenic strains to commonly used 236 
antibiotics in relation breakpoints set by the European committee on antimicrobial 237 
susceptibility testing. 238 
Antibiotic 
Number of isolates showing phenotypic 
resistance 
Percentage 
resistance 
Ampicillin 49 39.5 
Amoxicillim-clavulanic acid 45 36.3 
Piperacillcin-Tazobactam 0 0 
Ampicillin-Sulbactam 38 31 
Cephalexin 6 4.8 
Cefoxitin 3 2.4 
Cefotaxime 4 3.2 
Cefepime 1 0.8 
Imipenem 0 0 
Ertapenem 0 0 
Meropenem 0 0 
Aztreonam 4 3.2 
Gentamicin 2 1.6 
Amikacin 0 0 
Tetracycline 85 68.5 
Doxycycline 44 35.5 
Tigecycline 1 0.8 
Azithromycin 2 1.6 
Nalidixic acid 31 25 
Ciprofloxacin 4 3.2 
Sulfamethoxazole/trimethoprim 23 18.5 
Fosfomycin 1 0.8 
Chloramphenicol 14 11.3 
Nitrofurantonin 0 0 
Colistin 0 0 
 239 
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 240 
Results from the broth microtitre testing revealed MICs of 1024 mg/L for 241 
[Mn(CO)3(tpa-3N)]Br on all isolates (Table 2, S3 Table). MICs of 1 mg/L to colistin were 242 
observed for all isolates. In combination, MICs of the Mn complex were significantly 243 
reduced (P < 0.05) in the presence of colistin, with MICs reduced to ≤ 32 mg/L. Calculation 244 
of FICIs indicate synergy was produced between [Mn(CO)3(tpa-3N)]+ and colistin (FICIs 245 
0.129 – 0.281). It was found that UV activation (365 nm) had no impact on [Mn(CO)3(tpa-246 
3N)]+ MICs in this study. 247 
 248 
 249 
Fig 1. Growth curves of avian pathogenic E. coli strains 99/12 and 236/12 with and 250 
without exposure to UV light (365 nm) for 2.5 minutes. 251 
 252 
Relatively high MICs for the Mn complex are probably due to low membrane 253 
permeability of the entire compound. Previous research has shown that CO released from 254 
CORM readily reaches the intracellular environment, but the manganese-coligand moiety 255 
of the molecule does not, potentially due to lower permeability or lack of active transport 256 
into bacterial cells [14]. This could potentially limit the effectiveness of monotherapy with 257 
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CORMs in medical and veterinary applications; thus, as demonstrated in the studies 258 
presented here combination therapy maybe a favourable option. 259 
 260 
Table 2. Minimum inhibitory concentrations (MICs) of the Mn complex 261 
[Mn(CO)3(tpa-2N)]Br,  colistin and combinations of both versus multidrug-resistant 262 
strains of avian pathogenic Escherichia coli and corresponding fractional 263 
inhibitory concentration indices (FICIs). 264 
Strain no. MIC (mg/L) MIC in combination (mg/L)  FICI 
Mn complex colistin Mn complex + colistin colistin + Mn complex 
102/12 1024 0.5 4 0.125 0.25 
99/12 1024 1.5 0.5 0.25 0.17 
100/12 1024 1 0.5 0.25 0.25 
236/12 1024 1 0.5 0.25 0.25 
176/12 1024 0.5 2 0.125 0.25 
140/07 1024 1 32 0.25 0.281 
16/12 1024 1 1 0.25 0.251 
 265 
 266 
Data from the kill-kinetic assays indicate that although antimicrobial activity was 267 
observed in microtitre assays, in a non-static model, regrowth in the Mn complex-treated 268 
bacteria was observed (Fig. 2, S4 Table). The regrowth of cultures treated with the Mn 269 
complex 4 h post activation, suggests that the compound has a limited stability. This is 270 
potentially due to photodecomposition of the compound over time in ambient light. 271 
Colistin-treated cultures at 0.5 MIC produced good initial killing against both isolates 272 
tested, with regrowth observed after 2-4 h. Synergy observed in checkerboard assays of 273 
the CORM and colistin combination was confirmed in the kill-kinetic assays. The 274 
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combination showed markedly (P < 0.05) increased killing activity when compared to 275 
either Mn complex or colistin alone, with ≥ 3 log10 CFU/mL difference at 24 h. 276 
 277 
 278 
Fig 2. Time-kill curve of [Mn(CO)3(tpa-3N)]Br, colistin and combination of both 279 
agents (x1 MIC + 0.5 MIC) versus APEC strain a) 99/12 and b) 236/12 over 24 h. 280 
 281 
In vivo toxicity assays showed that G. mellonella survival numbers were reduced 282 
by 20% when exposed to 200 mg/kg of [Mn(CO)3(tpa-3N)]Br and by 30% when doses of 283 
400 mg/kg were administered (Fig. 3, S5 Table). Toxicity increased sharply when 600 284 
mg/kg was administered, with 100% larval mortality. Importantly, doses of 40 mg/kg, 285 
double the concentration required in treatment assays, produced no toxicity from the Mn 286 
complex. 287 
 288 
In vivo treatment assays found that combination therapy significantly increased 289 
larval survival over 96 h compared to monotherapy (Fig. 4, S6 Table). Little difference 290 
was observed between UV and non UV-exposed experiments, indicating that activation 291 
and perhaps CO alone, has little impact on the antibacterial activity in this model.  292 
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 293 
 294 
Fig 3. Survival curve showing in vivo toxicity of [Mn(CO)3(tpa-3N)]Br against 295 
Galleria mellonella over 48 h.  296 
 297 
 298 
 299 
Fig 4. Survival curves (live/dead) of G. mellonella over 96 h after infection with 105 300 
CFU/larvae of APEC strain a) 99/12 and b) 236/12 and treatment with PBS, 20mg/kg 301 
of [Mn(CO)3(tpa-3N)]Br, 0.625 mg/kg of colistin, and combination of both agents. 302 
 303 
High levels of morbidity were observed over 72 h with PBS- and Mn complex-304 
treated larvae, with large melanisation scores recorded (Fig. 5, S7 Table).  Low 305 
melanisation scores were observed in larvae treated with colistin alone and the Mn 306 
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complex-colistin combination, indicating these treatments reduce morbidity. Mn complex-307 
colistin production significantly lower (P < 0.004) melanisation scores than treatment with 308 
PBS or monotherapy with the Mn complex or colistin. Alongside its antibacterial activity, 309 
colistin has been previously shown to possess potent anti-endotoxin activity [23]. This 310 
could explain the reduced ‘shock’ to the larval immune system/lower melanisation scores, 311 
in larvae treated with colistin or the Mn complex-colistin combination. 312 
 313 
 314 
Fig 5. Melanisation assay in Galleria mellonella infected with 105 CFU/larvae of 315 
APEC strain a) 99/12 and b) 236/12 and treated with PBS, 20 mg/kg of [Mn(CO)3(tpa-316 
3N)]Br, colistin or a combination of both agents. Higher scores indicate greater 317 
insect morbidity.  318 
 319 
Bacterial counts over 24 h show that within larvae treated with PBS, bacterial 320 
numbers increased by >1.5 log10 CFU/100µL of hemolymph at 24 h (Fig 6, S8 Table). 321 
Treatment with colistin at 0.625 mg/kg initially reduced bacterial numbers of both 99/12 322 
and 236/12, before regrowth of both isolates was observed at 2 h. However, bacterial 323 
numbers at 24 h did not reach that of 0 h. Treatment with [Mn(CO)3(tpa-3N)]Br produced 324 
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initial bacterial killing, more significantly against 236/12, before regrowth was observed at 325 
4 h, resulting in bacterial numbers at 24 h reaching the original CFU/larvae at 0 h. This 326 
would indicate that in vivo, the Mn complex produces bacteriostatic action within the first 327 
24 h of administration. Bacterial counts indicate that the combination therapy was 328 
bactericidal and was significantly (P < 0.05) more effective in reducing bacterial numbers, 329 
than any monotherapy with [Mn(CO)3(tpa-3N)]Br, colistin or PBS, with total bacterial 330 
killing at 6 h for strain 236/12 and a reduction in CFU/100 µL of hemolymph to <1.5x101 331 
(Fig. 6).  332 
 333 
 334 
Fig 6. Bacterial counts over 24 h from G. mellonella post infection with 105 335 
CFU/larvae of APEC strain a) 99/12 and b) 236/12 and treatment with [Mn(CO)3(tpa-336 
3N)]Br, colistin, a combination of both agents or PBS. 337 
 338 
Although the mechanism of synergy remains to be determined, the observed 339 
activity is probably due to increased membrane permeability from the polymyxins, 340 
allowing greater amounts of the Mn complex inside the cell, thus increasing is ability to 341 
reach any potential target sites [24]. As the Mn complex also has the potential to distrupt 342 
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bacterial membranes, overall membrane disruption would be greater in the combination, 343 
resulting in increased cell leakage and eventual cell death. Due to this duel attack on 344 
bacterial membranes, concentrations of colistin required for antibacterial activity are 345 
lower. Not only is this beneficial in terms of reduced toxicity to patients/animals, but also 346 
to combat resistance to polymyxins. Other membrane permeabilisers such as 347 
nonapeptide [25] could be investigated for efficacy as an alternative to colistin, from which 348 
there is a risk of nephrotoxicity. 349 
Due to the original requirement of photoactivation to trigger the release of CO, it 350 
was assumed that the Mn complex would only serve as a model compound for 351 
fundamental studies on CO antibacterial activity, but with limited therapeutic applications. 352 
However, after investigation, it appears that its antibacterial action is not dependent on 353 
prior or post inoculation photoactivation in vivo. This fortuitous discovery, could increase 354 
the application of the compound from model system to the potential treatment of systemic 355 
infections in humans and animals.  356 
In conclusion, we believe this is the first study to examine the in vivo antibacterial 357 
activity of a manganese carbonyl complex. Its activity against avian pathogenic E. coli 358 
(APEC) significantly increases when used in conjunction with colistin. The work presented 359 
here clearly demonstrates that the combination also significantly reduces APEC colony 360 
forming units within G. mellonella over 24 h and also reduces larval morbidity due to 361 
APEC infection. The in vivo data here also confirm the in vitro results presented and 362 
indicates that UV activation of [Mn(CO)3(tpa-3)N)]Br is not required for its antibacterial 363 
activity. Further work should examine the activity of the title compound against other 364 
important humans and animal pathogens, such as Acinetobacter baumannii, 365 
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Pseudomonas aeruginosa and Staphylococcus aureus, which are also common carriers 366 
of antibiotic resistance genes and are associated with serious infections. It is clear that 367 
[Mn(CO)3(tpa-3)N)]Br and related compounds have potential for future applications in 368 
human and veterinary medicine. Furthermore, it appears that the antimicrobial activity of 369 
metal-carbonyl complexes does not necessarily always is based on the CO release 370 
efficiency [26]. 371 
 372 
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